New Delhi: Drugs Controller General of India (DCGI) on Monday approved Biological E’s Covid-19 vaccine Corbevax for emergency use among children aged 12-18 years.
The Hyderabad-based pharmaceutical company’s vaccine had earlier received emergency use authorization from DCGI’s Subject Expert Committee for the 12-18 age group, subject to conditions.
Corbevax, to be administered in two doses, is the third vaccine to be approved for 12-18-year olds in India, the others being Bharat Biotech’s Covaxin and Zydus Cadila’s DNA shot ZyCoV-D.
However, Covaxin is mainly being used currently to inoculate children aged 15-18 years.
Corbevax is expected to cost Rs 145 per dose, excluding taxes, ANI reported quoting sources.
National Technical Advisory Group on Immunisation (NTAGI) chief Dr NK Arora said earlier that Corbevax shots were safe, and offered good immunogenicity and higher antibody levels compared to other vector vaccines.
Bhubaneswar: Tigress Zeenat, who travelled nearly 200 km over two weeks from Odisha's Similipal, avoiding…
Bhubaneswar: The Odisha Government has dissolved the governing bodies or managing committees of all Non-Government…
New Delhi: President Droupadi Murmu on Monday appointed former Supreme Court judge Justice V Ramasubramanian…
Bhubaneswar: Marking a significant development in eco-friendly transport in Odisha, a tripartite Memorandum of Understanding…
Mumbai: After veteran actor Mukesh Khanna, noted poet Kumar Vishwas left netizens irked with his…
Bhubaneswar: A major fire erupted at a pressure cooker company godown at Satyanagar in Bhubaneswar…
This website uses cookies.